Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roger J Packer

Showing results (201-210 of 279) with videos related to

Pageof 28
Sort By:
Neuro-Oncology Advances|July 10, 2020
NCI-CONNECT: Comprehensive Oncology Network Evaluating Rare CNS Tumors-Histone Mutated Midline Glioma Workshop ProceedingsBrett J Theeler, Yamini Dalal, Michelle Monje, et al.
Neuro-Oncology|October 11, 2017
Longitudinal assessment of late-onset neurologic conditions in survivors of childhood central nervous system tumors: a Childhood Cancer Survivor Study reportElizabeth M Wells, Nicole J Ullrich, Kristy Seidel, et al.
The Journal of Pathology|May 19, 2023
Optical genome mapping identifies a novel pediatric embryonal tumor with a ZNF532::NUTM1 fusionMiriam Bornhorst, Augustine Eze, Surajit Bhattacharya, et al.
Child'S Nervous System : Chns : Official Journal of the International Society for Pediatric Neurosurgery|May 2, 2015
Phase I trial of weekly MK-0752 in children with refractory central nervous system malignancies: a pediatric brain tumor consortium studyLindsey M Hoffman, Maryam Fouladi, James Olson, et al.
Child'S Nervous System : Chns : Official Journal of the International Society for Pediatric Neurosurgery|July 20, 2015
A phase I trial and PK study of cediranib (AZD2171), an orally bioavailable pan-VEGFR inhibitor, in children with recurrent or refractory primary CNS tumorsMark W Kieran, Susan Chi, Stewart Goldman, et al.
Neurology. Genetics|August 11, 2021
Impact of MEK Inhibitor Therapy on Neurocognitive Functioning in NF1Karin S Walsh, Pamela L Wolters, Brigitte C Widemann, et al.
NPJ Precision Oncology|September 6, 2022
Circulating tumor DNA sequencing provides comprehensive mutation profiling for pediatric central nervous system tumorsErin R Bonner, Robin Harrington, Augustine Eze, et al.
Journal of Neuro-Oncology|June 5, 2025
Psychosocial functioning and determinants of the health-related quality of life in children with neurofibromatosis type 1 and cognitive impairmentsBelinda Barton, Pamela L Wolters, Karin S Walsh, et al.
Journal of Neuro-Oncology|April 14, 2017
Long-term neuropsychological follow-up of young children with medulloblastoma treated with sequential high-dose chemotherapy and irradiation sparing approachTaryn B Fay-McClymont, Danielle M Ploetz, Don Mabbott, et al.
Oncotarget|May 14, 2015
Proteomic profiling of high risk medulloblastoma reveals functional biologyJerome A Staal, Ling San Lau, Huizhen Zhang, et al.
Pageof 28

Showing results (201-210 of 279) with videos related to

Sort By:
Pageof 28
Neuro-Oncology Advances|July 10, 2020
NCI-CONNECT: Comprehensive Oncology Network Evaluating Rare CNS Tumors-Histone Mutated Midline Glioma Workshop ProceedingsBrett J Theeler, Yamini Dalal, Michelle Monje, et al.
Neuro-Oncology|October 11, 2017
Longitudinal assessment of late-onset neurologic conditions in survivors of childhood central nervous system tumors: a Childhood Cancer Survivor Study reportElizabeth M Wells, Nicole J Ullrich, Kristy Seidel, et al.
The Journal of Pathology|May 19, 2023
Optical genome mapping identifies a novel pediatric embryonal tumor with a ZNF532::NUTM1 fusionMiriam Bornhorst, Augustine Eze, Surajit Bhattacharya, et al.
Child'S Nervous System : Chns : Official Journal of the International Society for Pediatric Neurosurgery|May 2, 2015
Phase I trial of weekly MK-0752 in children with refractory central nervous system malignancies: a pediatric brain tumor consortium studyLindsey M Hoffman, Maryam Fouladi, James Olson, et al.
Child'S Nervous System : Chns : Official Journal of the International Society for Pediatric Neurosurgery|July 20, 2015
A phase I trial and PK study of cediranib (AZD2171), an orally bioavailable pan-VEGFR inhibitor, in children with recurrent or refractory primary CNS tumorsMark W Kieran, Susan Chi, Stewart Goldman, et al.
Neurology. Genetics|August 11, 2021
Impact of MEK Inhibitor Therapy on Neurocognitive Functioning in NF1Karin S Walsh, Pamela L Wolters, Brigitte C Widemann, et al.
NPJ Precision Oncology|September 6, 2022
Circulating tumor DNA sequencing provides comprehensive mutation profiling for pediatric central nervous system tumorsErin R Bonner, Robin Harrington, Augustine Eze, et al.
Journal of Neuro-Oncology|June 5, 2025
Psychosocial functioning and determinants of the health-related quality of life in children with neurofibromatosis type 1 and cognitive impairmentsBelinda Barton, Pamela L Wolters, Karin S Walsh, et al.
Journal of Neuro-Oncology|April 14, 2017
Long-term neuropsychological follow-up of young children with medulloblastoma treated with sequential high-dose chemotherapy and irradiation sparing approachTaryn B Fay-McClymont, Danielle M Ploetz, Don Mabbott, et al.
Oncotarget|May 14, 2015
Proteomic profiling of high risk medulloblastoma reveals functional biologyJerome A Staal, Ling San Lau, Huizhen Zhang, et al.
Pageof 28